108 related articles for article (PubMed ID: 15739019)
1. Prognostic and predictive value of cathepsins D and L in operable breast cancer patients.
Jagodic M; Vrhovec I; Borstnar S; Cufer T
Neoplasma; 2005; 52(1):1-9. PubMed ID: 15739019
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
Harbeck N; Alt U; Berger U; Krüger A; Thomssen C; Jänicke F; Höfler H; Kates RE; Schmitt M
Clin Cancer Res; 2001 Sep; 7(9):2757-64. PubMed ID: 11555589
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer.
Thomssen C; Schmitt M; Goretzki L; Oppelt P; Pache L; Dettmar P; Jänicke F; Graeff H
Clin Cancer Res; 1995 Jul; 1(7):741-6. PubMed ID: 9816040
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer.
Harbeck N; Alt U; Berger U; Kates R; Krüger A; Thomssen C; Jänicke F; Graeff H; Schmitt M
Int J Biol Markers; 2000; 15(1):79-83. PubMed ID: 10763146
[TBL] [Abstract][Full Text] [Related]
5. Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L.
Thomssen C; Oppelt P; Jänicke F; Ulm K; Harbeck N; Höfler H; Kuhn W; Graeff H; Schmitt M
Anticancer Res; 1998; 18(3C):2173-80. PubMed ID: 9703780
[TBL] [Abstract][Full Text] [Related]
6. Cathepsin expression in oral squamous cell carcinoma: relationship with clinicopathologic factors.
Kawasaki G; Kato Y; Mizuno A
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2002 Apr; 93(4):446-54. PubMed ID: 12029284
[TBL] [Abstract][Full Text] [Related]
7. Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators.
Lah TT; Cercek M; Blejec A; Kos J; Gorodetsky E; Somers R; Daskal I
Clin Cancer Res; 2000 Feb; 6(2):578-84. PubMed ID: 10690542
[TBL] [Abstract][Full Text] [Related]
8. Cathepsin D, B and L circulating levels as prognostic markers of malignant progression.
Tumminello FM; Leto G; Pizzolanti G; Candiloro V; Crescimanno M; Crosta L; Flandina C; Montalto G; Soresi M; Carroccio A; Bascone F; Ruggeri I; Ippolito S; Gebbia N
Anticancer Res; 1996; 16(4B):2315-9. PubMed ID: 8694562
[TBL] [Abstract][Full Text] [Related]
9. Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients.
Kos J; Stabuc B; Schweiger A; Krasovec M; Cimerman N; Kopitar-Jerala N; Vrhovec I
Clin Cancer Res; 1997 Oct; 3(10):1815-22. PubMed ID: 9815568
[TBL] [Abstract][Full Text] [Related]
10. Cells producing cathepsins D, B, and L in human breast carcinoma and their association with prognosis.
Lah TT; Kalman E; Najjar D; Gorodetsky E; Brennan P; Somers R; Daskal I
Hum Pathol; 2000 Feb; 31(2):149-60. PubMed ID: 10685628
[TBL] [Abstract][Full Text] [Related]
11. Lysosomal aspartic and cysteine proteinases serum levels in patients with pancreatic cancer or pancreatitis.
Leto G; Tumminello FM; Pizzolanti G; Montalto G; Soresi M; Carroccio A; Ippolito S; Gebbia N
Pancreas; 1997 Jan; 14(1):22-7. PubMed ID: 8981503
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of cathepsins B and L in primary human breast cancer.
Foekens JA; Kos J; Peters HA; Krasovec M; Look MP; Cimerman N; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
J Clin Oncol; 1998 Mar; 16(3):1013-21. PubMed ID: 9508185
[TBL] [Abstract][Full Text] [Related]
13. Cathepsin B, cathepsin H, cathepsin X and cystatin C in sera of patients with early-stage and inflammatory breast cancer.
Decock J; Obermajer N; Vozelj S; Hendrickx W; Paridaens R; Kos J
Int J Biol Markers; 2008; 23(3):161-8. PubMed ID: 18949742
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer.
Castiglioni T; Merino MJ; Elsner B; Lah TT; Sloane BF; Emmert-Buck MR
Hum Pathol; 1994 Sep; 25(9):857-62. PubMed ID: 8088759
[TBL] [Abstract][Full Text] [Related]
15. Serum cathepsin H as a potential prognostic marker in patients with colorectal cancer.
Schweiger A; Christensen IJ; Nielsen HJ; Sørensen S; Brünner N; Kos J
Int J Biol Markers; 2004; 19(4):289-94. PubMed ID: 15646835
[TBL] [Abstract][Full Text] [Related]
16. Prognostic markers in node-negative breast cancer: a prospective study.
Kute TE; Russell GB; Zbieranski N; Long R; Johnston S; Williams H; Stackhouse C; Wilkins L; Evans I; Berry P; Rimmer K; Tucker E
Cytometry B Clin Cytom; 2004 May; 59(1):24-31. PubMed ID: 15108167
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients.
Gasparini G; Toi M; Verderio P; Ranieri G; Dante S; Bonoldi E; Boracchi P; Fanelli M; Tominaga T
Int J Oncol; 1998 May; 12(5):1117-25. PubMed ID: 9538138
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of cysteine proteinases cathepsins B and L and their endogenous inhibitors stefins A and B in patients with squamous cell carcinoma of the head and neck.
Strojan P; Budihna M; Smid L; Svetic B; Vrhovec I; Kos J; Skrk J
Clin Cancer Res; 2000 Mar; 6(3):1052-62. PubMed ID: 10741734
[TBL] [Abstract][Full Text] [Related]
19. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.
Mehta RR; McDermott JH; Hieken TJ; Marler KC; Patel MK; Wild LD; Das Gupta TK
J Clin Oncol; 1998 Jul; 16(7):2409-16. PubMed ID: 9667258
[TBL] [Abstract][Full Text] [Related]
20. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer.
Isola J; Weitz S; Visakorpi T; Holli K; Shea R; Khabbaz N; Kallioniemi OP
J Clin Oncol; 1993 Jan; 11(1):36-43. PubMed ID: 8093367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
